Synaps Dx offers DISCERN™, a validated diagnostic test that utilizes a simple skin sample to accurately identify and differentiate Alzheimer's disease from other dementias. This technology addresses the issue of misdiagnosis, as up to 30% of Alzheimer's cases may be incorrectly identified, leading to inappropriate treatment decisions for patients.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Up to 30% of Alzheimer's cases are misdiagnosed, leading to inappropriate treatment decisions. Traditional diagnostic methods often fail to differentiate Alzheimer's disease from other forms of dementia, resulting in delayed or ineffective care.
Solution
Synaps Dx offers DISCERN™, a diagnostic test that utilizes a simple skin sample to accurately identify and differentiate Alzheimer's disease from other dementias. The test provides healthcare professionals with scientific data to distinguish Alzheimer's Disease from other dementias, addressing the issue of misdiagnosis. DISCERN™ aims to empower millions of patients with more accurate and confident treatment decisions by enhancing healthcare with necessary scientific data. The test is validated as a gold standard for identifying and distinguishing Alzheimer's disease from other forms of dementia.
Target Audience
The primary users are healthcare professionals, including physicians and researchers, who require accurate diagnostic tools for Alzheimer's disease and other dementias. It is also intended for patients with dementia.
Features
- Utilizes a simple skin sample for analysis.
- Differentiates Alzheimer's disease from other dementias.
- Provides accurate diagnostic results to minimize misdiagnosis.
- Offers scientific data to support healthcare professionals in making informed decisions.
- CLIA-regulated as an accredited laboratory to perform high complexity clinical testing.